BRIM Biotechnology (TPE:6885) Notes Receivable: NT$0.00 Mil (As of Dec. 2025)


TPE:6885 BRIM Biotechnology Inc TPE:6885
40 GF Score
Price NT$21.75
GF Value NT$486.91
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BRIM Biotechnology Notes Receivable?

BRIM Biotechnology TPE:6885 -0.46% 40 Notes Receivable is NT$0.00 Mil as of Dec. 2025. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$486.91 (Possible Value Trap). The stock has 4 warning signs investors should review.

BRIM Biotechnology's Notes Receivable for the quarter that ended in Dec. 2025 was NT$0.00 Mil.

BRIM Biotechnology Notes Receivable Related Terms

BRIM Biotechnology Notes Receivable Historical Data

* Premium members only.

The historical data trend for BRIM Biotechnology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRIM Biotechnology Notes Receivable Chart

BRIM Biotechnology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BRIM Biotechnology Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6885
40GF Score
BRIM Biotechnology Inc TPE:6885
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRIM Biotechnology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of NT$0.00 Mil mean?
BRIM Biotechnology (TPE:6885) has a Notes Receivable of NT$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BRIM Biotechnology and its competitors.
Is BRIM Biotechnology's Notes Receivable too high?
BRIM Biotechnology's current Notes Receivable is NT$0.00 Mil. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's Notes Receivable compare to VRTX and REGN?
BRIM Biotechnology's Notes Receivable of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BRIM Biotechnology and its competitors. BRIM Biotechnology's current Notes Receivable is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current Notes Receivable is NT$0.00 Mil. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current Notes Receivable is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?

Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued. The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91. GuruFocus considers BRIM Biotechnology to be Possible Value Trap.

Key valuation signals for TPE:6885:

  • Notes Receivable: NT$0.00 Mil
  • GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRIM Biotechnology Business Description

Address Alley 30, Lane 358, Ruiguang Road, 8th Floor, No.1, Neihu District, Taipei, TWN, 11492
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score

Get the complete analysis for TPE:6885

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.75
Price
NT$486.91
GF Value